Endothelial dysfunctions: Common denominators in vascular disease

Current Opinion in Lipidology

Volumn 11, Issue 1, 2000, Pages 9-23

  De Caterina, Raffaele ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; ENDOTHELIUM LESION; HUMAN; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HUMANS; RISK FACTORS; VASCULAR DISEASES; VASODILATION;

EID: 0034114708     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200002000-00003     Document Type: Review

References (117)

1. 1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
2. 2 Gimbrone MA Jr, Kume N, Cybulsky MI. Vascular endothelial dysfunction and the pathogenesis of atherosclerosis. In: Atherosclerosis reviews. Weber PC, Leaf A (editors). New York: Raven Press; 1993. pp. 000-000.
3. 3 Gimbrone MA Jr. Vascular endothelium in health and disease. In: Molecular cardiovascular medicine. Haber E (editor). New York, NY: Scientific American Medicine; 1995; 75(6): 67B-70B.
4. 4 De Caterina R, Gimbrone MA Jr. Leukocyte-endothelial interactions and the pathogenesis of atherosclerosis. In: n-3 Fatty acids: prevention and treatment in vascular disease. Kristensen SD, Schmidt EB, De Caterina R, Endres S (editors). London: Springer Verlag; 1995. pp. 9-24.
5. 5 Cybulsky MI, Gimbrone MA Jr. Endothelial-leukocyte adhesion molecules in acute inflammation and atherogenesis. In: Endothelial cell dysfunctions. Simionescu N, Simionescu M (editors). New York: Plenum Press; 1992. pp. 129-140.
6. 6 Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791.
7. 7 Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13:197-204.
8. 8 Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994; 76:253-262.
9. 9 Collins T. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68:499-508.
10. 10 Marui N, Offermann MK, Swerlick R, Kunsck C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
11. 11 Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9:899-909.
12. 12 Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116:1292-1300.
13. 13 Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterolfed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 1989; 9:908-918.
14. 14 Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
15. 15 Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic - dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
16. 16 Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96:1395-1403.
17. 17 Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5:293-302.
18. 18 Karino T, Motomiya M. Flow visualization in isolated transparent natural blood vessels. Biorheology 1983; 20:119-127.
19. 19 Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 1983; 53:502-14.
20. 20 Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14:133-40.
21. 21 Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995; 75:519-560.
22. 22 Resnick N, Gimbrone MA Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J 1995; 9:874-882.
23. 23 Osawa M, Masuda M, Harada N, Lopes RB, Kano Y, Fujiwara K. Tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) in mechanically stimulated vascular endothelial cells. Eur J Cell Biol 1997; 72:229-37.
24. 24 Satcher RL Jr, Bussolari SR, Gimbrone MA Jr, Dewey CF Jr. The distribution of fluid forces on model arterial endothelium using computational fluid dynamics. J Biochem Eng 1992; 114:309-316.
25. 25 Barbee KA, Mundel T, Lal R, Davies PF. Subcellular distribution of shear stress at the surface of flow-aligned and nonaligned endothelial monolayers. Am J Physiol 1995; 268:H1765-H1772.
26. 26 Gimbrone MA Jr, Topper JN. Biology of the vessel wall. In: Molecular basis of heart diseases. Chien KR, Breslow JR, Leiden JM, Rosenberg RD, Seidman C (editors). Philadelphia: WB Saunders; 1997.
27. 27 Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxyde synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93:10417-10422.
28. 28 Ando J, Tsuboi H, Korenaga R, Takada Y, Toyama-Sorimachi N, Miyasaka M, Kamiya A. Shear stress inhibits adhesion of cultured endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am J Physiol 1994; 267:C679-C687.
29. 29 Varner SE, Nerem RM, Medford RM, Alexander RW. Laminar shear stress regulates VCAM-1 gene expression [Abstract], Ann Biomed Eng 1994; 22:40a.
30. 30 Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res 1996; 79:984-991.
31. 31 De Caterina R, Libby P, Peng H-B, Thannickal V, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60-68.
32. 32 Khan BV, Harrison DG, Olbrych MT. Alexander RW, Medford RM. Nitric oxide regulated vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93:9114-9119.
33. 33 Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997; 99:1809-1813.
34. 34 Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci 1992; 667:324-331.
35. 35 Gianetti J, Vaghetti M, Petronio S, Mariani M, De Caterina R. Soluble-phase adhesion molecules as biohumoral markers of vascular activation in vivo [in Italian]. Cardiologia 1999; 44:125-136. This is a comprehensive review on soluble adhesion molecules in cardiovascular diseases.
36. 36 De Caterina R, Basta G, Lazzerini G, Bernini W, Dell'Omo G, Petrucci R, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atheroclerosis [Abstract]. Eur Heart J 1996; 17(Suppl 86):.
37. 37 Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17:503-512.
38. 38 Ridker P, Hennekens C, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92. This is a spin-off of the Physician's Health Study, reporting on the predictive value of soluble ICAM-1 on future cardiovascular events in a cohort of healthy physicians. Soluble ICAM-1 also correlates with a systemic index of inflammation: C-reactive protein.
39. 39 Pigott R, Dillon L, Hemingway I, Gearing A. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187:584-589.
40. 40 Newman WP, Middaugh JP, Propst MT, Rogers DR. Atherosclerosis in Alaska Natives and non-natives. Lancet 1993; 341:1056-1057.
41. 41 von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary ω-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130:554-562. This controlled study indicated a favourable effect of n-3 fatty acids on coronary atherosclerosis progression in humans.
42. 42 De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of pro-atherogenic and pro-inflammatory proteins in human endothelial cells. Arterioscler Thromb 1994; 14:1829-1836.
43. 43 De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. Omega-3 fatty acids and endothelial leukocyte adhesion molecules. Prostagl Leukotr Ess Fatty Acids 1995; 52:192-195.
44. 44 De Caterina R, Libby P. Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids 1996; 31(Suppl 1):557-563.
45. 45 De Caterina R, Libby P, Peng H-B, Thannickal V, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60-68.
46. 46 Shin W, Hong Y, Peng H, De Caterina R, Libby P, Liao J. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity. J Biol Chem 1996; 271:11317-11324.
47. 47 Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98:36-42.
48. 48 Simoncini T, De Caterina R, Genazzani AR. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 1999; 84:815-818. This original paper indicated the effects of natural oestrogens, and of selective estrogen receptor modulators on the endothelial expression of adhesion molecules and on monocytoid cell adhesion.
49. 49 Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995; 75:75B-81B.
50. 50 Huraux C, Makita T, Kurz S, Yamaguchi K, Szlam F, Tarpey MM, et al. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. Circulation 1999; 99:53-59. This original paper indicated the relationship of increased superoxide production and the impaired vasodilatation in human arteries in the presence of risk factors for cardiovascular disease.
51. 51 Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redoxactivated forms. Science 1992; 258:1898-1902.
52. 52 Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nature Struct Biol 1998; 5:247-249. An updated review on the topic is presented.
53. 53 Garg U, Hassid A. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
54. 54 Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89:7674-7677.
55. 55 Upchurch GR, Welch GN, Loscalzo J. Homocysteine, EDRF and endothelial function, J Nutr 1996; 126(Suppl):1290S-1294S.
56. 56 Anderson TJ, Meredith IT, Charboneau F, Yeung AC, Frei B, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93:1647-1650.
57. 57 Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993; 91:29-37.
58. 58 Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
59. 59 Hirooka Y, Egashira K, Imaizumi T. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol 1994; 24:948-955.
60. 60 Quyyumi AA. Endothelial function in health and disease: new insight into the genesis of cardiovascular disease. Am J Med 1998; 105:32S-39S.
61. 61 Lüscher TF, Noll G. Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens 1996; 14(Suppl 2):S111-S121.
62. 62 Limbruno U, Petronio AS, Amoroso G, Baglini R, Paterni G, Merelli A, et al. The impact of coronary artery disease on coronary vasomotor response to non-ionic contrast media. Circulation 2000 (in press).
63. 63 Ruschitzka FT, Noll G, Lüscher TF. The endothelium in coronary artery disease. Cardiology 1997; 88(Suppl 3):3-19.
64. 64 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor produced by vascular endothelial cells. Nature 1988; 332:411-415.
65. 65 Lerman A, Edwards BS, Hallet JW, Heublin DM, Sandberg SM, Burnett JCJ. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001.
66. 66 Lerman A, Kubo SH, Tschumperlin LK, Burnett JCJ. Plasma endothelin levels in humans with end stage heart failure and after cardiac transplantation. J Am Coll Cardiol 1992; 20:849-853.
67. 67 Haynes W, Webb DJ. Contribution of endogenous degeneration of endothelin-1 to basal vascular tone. Lancet 1994; 344:852-854.
68. 68 Lerman A, Holmes DRJ, Bell MR, Garratt KN, Nishimura RA, Burnett JCJ. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92:2426-2431.
69. 69 Kaski JC, Elliot PM, Salomone O, Dickinson K, Gordon D, Hann C, Holt DW. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 1995; 74:620-624.
70. 70 Cannan CR, Mathew V, Lerman A. New insight into coronary endothelial dysfunction: role of endothelin. J Lab Clin Med 1998; 131:300-305. This is an updated review on the topic.
71. 71 Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79:691-705. This is an updated review on the topic.
72. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 1990; 15:699-703.
73. 73 Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
74. 74 Caldwell PR, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin-converting enzyme. Vascular endothelial location. Science 1976; 191:1050-1051.
75. 75 Okamura T, Okunishi H, Ayajiki K, Toda H. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol 1990; 15:353-359.
76. 76 Dzau VJ. Short-and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems. J Cardiovasc Pharmacol 1989; 14(Suppl 4):S1-S5.
77. 77 Timmermanns PBMWM, Benfield P, Chiu AT, Herbin WF, Wong PC, Smith RD, et al. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5:221S-235S.
78. 78 Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411-1420. This is an updated review on the topic of angiotensin-converting enzyme inhibitors.
79. 79 Neutel JM. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999; 84:13K-17K. This is an updated review on the topic of angiotensin II receptor antagonists.
80. 80 Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman B, Griendling K, Harrison D. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contributions to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
81. 81 Griendling K, Ollerenshaw JD, Minieri CA, Alexander RW. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
82. 82 Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
83. 83 Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
84. 84 Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995; 346:467-471.
85. 85 Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-265.
86. 86 Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24:499-505.
87. 87 Taddei S, Virdis A, Mattei P, Ghiadoni L, Salvetti A. Effect of lisinopril on endothelial function. J Hypertens 1998; 16:447-456. This paper reported on the favourable effects of the ACE inhibitor lisinopril on endothelium-dependent vasodilatation in response to acetylcholine.
88. 88 Virdis A, Ghiadoni L, Sudano I, Taddei S, Salvetti A. Effect of antihypertensive drugs on endothelial function in humans. J Hypertens 1998; 16(Suppl 8):S103-S110. This is an updated comprehensive review on the topic.
89. 89 Küng CF, Tschudi MR, Noll G, Clozel JP, Lüscher TF. Effects of the calcium-antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995; 26:312-318.
90. 90 Yang Z, Bauer E, von Segesser SL, Stulz P, Turina M, Lüscher TF. Differential mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 16:654-660.
91. 91 Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994; 89:2212-2218.
92. 92 Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30:1606-1612.
93. 93 Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335:1109-1113.
94. 94 Furberg CF, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-1331.
95. 95 Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willet WC. Vitamin E consumption and the risk of coronary disease in women, N Engl J Med 1993; 328:1444-1449.
96. 96 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-1456.
97. 97 Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross cultural epidemiology. Am J Clin Nutr 1991; 1991:326-334.
98. 98 Riemersma RA, Wood DA, Macintyre CCA, Eltin RA, Gey KF, Liver MF. Risk of angina pectoris and plasma concentration of vitamins A, C, and E and beta carotene. Lancet 1991; 337:1-5.
99. 99 Rapola JM, Virtamo F, Haukka FK. Effect of vitamin E and beta carotene on the incidence of angina pectoris: a randomized, double-blind, controlled trial. JAMA 1996; 275:693-698.
100. 100 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman J, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
101. 101 Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715-1720.
102. 102 Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-455. This is a report of a large controlled prospective trial of a low dose of n-3 fatty acids after an acute myocardial infarction. An important reduction in total and cardiovascular mortality with n-3 fatty acids on top of currently used medications was reported. In this study, no effect of vitamin E, either alone or in addition to n-3 fatty acids, was found.
103. 103 Heart Outcomes Prevention Evaluation (HOPE) Study Group. Heart Outcomes Prevention Evaluation (HOPE): main results. Atlanta, Georgia: 1999. This is a recent report of lack of effect of vitamin E on cardiovascular events in a high-risk population, which was contrary to a large favourable effect of the ACE inhibitor ramipril.
104. 104 Gilligan DM, Sack MN, Guetta V, Casino PR, Quyyumi AA, Rader DJ. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994; 24:1611-1617.
105. 105 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-1037.
106. 106 The Writing Group of the PEPI Trial. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens in heart disease risk factors in postmenopausal women. JAMA 1995; 273:199-208.
107. 107 Nabulsi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. No association of menopause and hormone replacement therapy with carotid intima-media thickness. Circulation 1996; 94:1857-1863.
108. 108 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613. This is the first prospective randomized placebo-controlled trial of hormone replacement therapy on total and cardiovascular mortality in postmenopausal women. During an average follow up of 4,1 years, treatment with oral conjugated equine oestrogen plus medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events. This was interpreted as being due to some increase in thrombotic deaths and events caused by oestrogens. It is still possible that an antiatherogenic effect of oestrogen was present, but missed during the relatively short follow up of the study.
109. 109 Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995; 214:847-855.
110. 110 Reis SE, Gloth ST, Blumenthal RS. Ethinyl estradiol acutely attenuates coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994; 89:52-60.
111. 111 Gilligan DM, Quyyumi A, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89:2545-2551.
112. 112 Gilligan DM, Badar DM, Panza JA. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995; 75:264-268.
113. 113 Lieberman EH, Gerhard MD, Uehata A. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
114. 114 Rosano GMC, Sarrel PM, Poole-Wilson PA. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342:133-136.
115. 115 Rosano GMC, Peters NS, Lefroy D, Lindsay DC, Sarrel PM, Collins P, Poole-Wilson PA. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X. J Am Coll Cardiol 1996; 28:1500-1505.
116. 116 Armstead VE, Minchenko AG, Schuhl RA, Hayward R, Nossuli TO, Lefer AM. Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol 1997; 273:H740-H746.
117. 117 Huie RE, Padmaja S. Reaction of nitric oxide with superoxide anion. Free Radical Res Commun 1993; 18:195-200.